The 10-second takeaway
For the quarter ended Dec. 31 (Q2), ImmunoGen crushed expectations on both revenues and earnings per share.
Compared to the prior-year quarter, revenue increased significantly and GAAP earnings per share shrank.
Margins increased across the board.
Immunogen tallied revenue of $7.6 million. The six analysts polled by S&P Capital IQ expected to see revenue of $5.4 million. Sales were 82% higher than the prior-year quarter's $4.2 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions.
EPS came in at -$0.17. The six earnings estimates compiled by S&P Capital IQ predicted -$0.23 per share. GAAP EPS were -$0.17 for Q2 compared to -$0.21 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Figures may be non-GAAP to maintain comparability with estimates.
For the quarter, gross margin was 100%, 38,310 basis points better than the prior-year quarter. Operating margin was -167.7%, 20,360 basis points better than the prior-year quarter. Net margin was -167.4%, 17,330 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $6.5 million. On the bottom line, the average EPS estimate is -$0.22.
Next year's average estimate for revenue is $21.3 million. The average EPS estimate is -$0.95.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 270 members out of 290 rating the stock outperform, and 20 members rating it underperform. Among 79 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 76 give ImmunoGen a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on ImmunoGen is outperform, with an average price target of $15.40.
The biotechnology and health-care investing landscape is littered with also-rans and a few major winners. Is ImmunoGen the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company Fool co-founder David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
- Add Immunogen to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.